Margaret Gatti-Mays: A great option for our patients with TNBC
Margaret Gatti-Mays, Associate Professor in the Division of Medical Oncology at the OSUCCC – James Cancer Hospital and Solove Research Institute, shared Dana-Farber’s Breast Oncology Center’s post on X/Twitter, adding:
“Excited to be opening OptimICE-pCR at Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute SSCBC soon! A great option for our patients with TNBC and will help answer an important question regarding need of adjuvant pembrolizumab in patients with pCR after neoadjuvant chemo-IO.”
Quoting Dana-Farber’s Breast Oncology Center’s post:
“Poster PO4-19-05 | OptimICE-pCR De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemo + checkpoint inhibitor therapy.”
Source: Margaret Gatti-Mays/X and Dana-Farber’s Breast Oncology Center/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023